Literature DB >> 22167405

Pneumocystis pneumonia.

Shelley A Gilroy1, Nicholas J Bennett.   

Abstract

Pneumocystis (carinii) jiroveci pneumonia can occur in immunocompromised individuals, especially hematopoietic stem and solid organ transplant recipients and those receiving immunosuppressive agents, and is the most common opportunistic infection in persons with advanced human immunodeficiency virus (HIV) infection. The Pneumocystis genus was initially mistaken as a trypanosome and later as a protozoan. Genetic analysis identified the organism as a unicellular fungus. Pneumocystis jiroveci is the species responsible for human infections. A slow indolent time course with symptoms of pneumonia progressing over weeks to months is characteristic in HIV-infected patients. Fulminant respiratory failure associated with fever and dry cough is typical in non-HIV-infected patients. Definitive diagnosis relies on histopathological testing of sputum, induced or sampled by fiberoptic bronchoscopy with bronchoalveolar lavage. The first-line drug for treatment and prevention is trimethoprim-sulfamethoxazole. © Thieme Medical Publishers.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22167405     DOI: 10.1055/s-0031-1295725

Source DB:  PubMed          Journal:  Semin Respir Crit Care Med        ISSN: 1069-3424            Impact factor:   3.119


  17 in total

1.  Cost-effectiveness of Prophylaxis Against Pneumocystis jiroveci Pneumonia in Patients with Crohn's Disease.

Authors:  Philip N Okafor; Francis A Farraye; Adetoro T Okafor; Daniel O Erim
Journal:  Dig Dis Sci       Date:  2015-07-16       Impact factor: 3.199

2.  Diffuse cystic lung diseases: differential diagnosis.

Authors:  Bruno Guedes Baldi; Carlos Roberto Ribeiro Carvalho; Olívia Meira Dias; Edson Marchiori; Bruno Hochhegger
Journal:  J Bras Pneumol       Date:  2017 Mar-Apr       Impact factor: 2.624

3.  Increased risk of pneumocystis jiroveci pneumonia among patients with inflammatory bowel disease.

Authors:  Millie D Long; Francis A Farraye; Philip N Okafor; Christopher Martin; Robert S Sandler; Michael D Kappelman
Journal:  Inflamm Bowel Dis       Date:  2013-04       Impact factor: 5.325

Review 4.  Novel adjunctive therapies for the treatment of tuberculosis.

Authors:  A A Ordonez; M Maiga; S Gupta; E A Weinstein; W R Bishai; S K Jain
Journal:  Curr Mol Med       Date:  2014-03       Impact factor: 2.222

Review 5.  PharmGKB summary: very important pharmacogene information for N-acetyltransferase 2.

Authors:  Ellen M McDonagh; Sotiria Boukouvala; Eleni Aklillu; David W Hein; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2014-08       Impact factor: 2.089

6.  Incidence of Pneumocystis jirovecii pneumonia after temozolomide for CNS malignancies without prophylaxis.

Authors:  Alexander J Neuwelt; Tam M Nguyen; Rongwei Fu; Joseph Bubalo; Rose Marie Tyson; Cynthia Lacy; Seymur Gahramanov; Morad Nasseri; Penelope D Barnes; Edward A Neuwelt
Journal:  CNS Oncol       Date:  2014-07

Review 7.  Potential Impact of Co-Infections and Co-Morbidities Prevalent in Africa on Influenza Severity and Frequency: A Systematic Review.

Authors:  Adam L Cohen; Meredith McMorrow; Sibongile Walaza; Cheryl Cohen; Stefano Tempia; Marissa Alexander-Scott; Marc-Alain Widdowson
Journal:  PLoS One       Date:  2015-06-11       Impact factor: 3.240

8.  Pneumocystis Pneumonia in Patients with Autoimmune Diseases: A Retrospective Study Focused on Clinical Characteristics and Prognostic Factors Related to Death.

Authors:  Minjiang Chen; Xinlun Tian; Fang Qin; Jiong Zhou; Jinjing Liu; Mengzhao Wang; Kai-Feng Xu
Journal:  PLoS One       Date:  2015-09-30       Impact factor: 3.240

9.  The incidence, mortality and timing of Pneumocystis jiroveci pneumonia after hematopoietic cell transplantation: a CIBMTR analysis.

Authors:  K M Williams; K W Ahn; M Chen; M D Aljurf; A L Agwu; A R Chen; T J Walsh; P Szabolcs; M J Boeckh; J J Auletta; C A Lindemans; J Zanis-Neto; M Malvezzi; J Lister; J S de Toledo Codina; K Sackey; J L H Chakrabarty; P Ljungman; J R Wingard; M D Seftel; S Seo; G A Hale; B Wirk; M S Smith; B N Savani; H M Lazarus; D I Marks; C Ustun; H Abdel-Azim; C C Dvorak; J Szer; J Storek; A Yong; M R Riches
Journal:  Bone Marrow Transplant       Date:  2016-01-04       Impact factor: 5.483

10.  Rapid and precise diagnosis of pneumonia coinfected by Pneumocystis jirovecii and Aspergillus fumigatus assisted by next-generation sequencing in a patient with systemic lupus erythematosus: a case report.

Authors:  Yili Chen; Lu Ai; Yingqun Zhou; Yating Zhao; Jianyu Huang; Wen Tang; Yujian Liang
Journal:  Ann Clin Microbiol Antimicrob       Date:  2021-06-26       Impact factor: 3.944

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.